Novartis announced on Tuesday that it will acquire New York-based Tourmaline Bio in a deal valued at approximately $1.4 billion.
Under the agreement, Novartis will pay $48 per share for Tourmaline, adding a late-stage cardiovascular treatment to its development pipeline.
The acquisition, already unanimously approved by both companies’ boards, underscores Novartis’ commitment to strengthening its position in the cardiovascular therapeutics space.
Focus on Promising Therapy
Tourmaline’s lead program, pacibekitug, is a targeted therapy designed to reduce systemic inflammation linked to atherosclerotic cardiovascular disease.
The drug candidate is Phase III-ready and expected to play a key role in expanding treatment options for patients facing one of the world’s most persistent health challenges.
Novartis highlighted that the addition of pacibekitug complements its existing cardiovascular disease assets and could help address unmet medical needs in the market.
Next Steps in the Transaction
Novartis will soon launch a tender offer to acquire all outstanding shares of Tourmaline’s common stock.
Once completed, Tourmaline will operate as an indirect, wholly owned subsidiary of Novartis.
The transaction is expected to close in the fourth quarter of 2025, pending customary regulatory approvals and closing conditions.